BRONCUS CHINA
{{company.company_channel.channel_name}}
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Broncus Medical (02216.HK) Announces Annual Results for 2023 2024-03-28 22:32
Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang 2023-11-24 09:19
Broncus Announced Long-Term Follow-Up Data on InterVapor, Showing Stable Long-Term Efficacy in Patients 2023-09-18 17:36
Broncus Medical (02216.HK) Announces Interim Results for 2023 2023-08-30 23:49
6-Month Registered Clinical Trial Data on World's First Transbronchial Pulmonary Radiofrequency Ablation System for Lung Cancer Announced, Showing Significant Efficacy 2023-08-07 20:41
BRONCUS COMPLETES THE FIRST CASE OF REGISTERED CLINICAL TRIALS OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY ABLATION SYSTEM 2023-07-10 12:56
Broncus Medical (02216.HK) Announces Annual Results for 2022 2023-03-30 01:05
BRONCUS'S DISPOSABLE NEBULIZING MICRO-CATHETER FOR ENDOSCOPE WAS APPROVED FOR MARKETING IN CHINA AND ITS APPLICATIONS IN DRUG-DEVICE COMBINATION WILL BE BROADENED 2022-10-31 16:07
Broncus (02216.HK) announced interim results 2022-08-31 22:04
BRONCUS COMPLETED SURGERIES ON THE FIRST GROUP OF PATIENTS USING ITS InterVapor®, THE THERMAL VAPOR TREATMENT SYSTEM, AFTER APPROVED FOR MARKETING IN CHINA 2022-07-18 18:11
Broncus Medical (02216.HK) Announces Annual Results for 2021: Operating revenue for 2021 increased 234.2% year-on-year, while product development and commercialization are steadily advancing. 2022-03-30 21:58
INTERVAPOR®, THERMAL VAPOR TREATMENT SYSTEM, APPROVED FOR MARKETING IN CHINA 2022-03-22 10:34
INTERVAPOR®, THERMAL VAPOR TREATMENT SYSTEM, APPROVED FOR MARKETING IN CHINA 2022-03-21 17:07
Broncus enter into strategic partnership with New Frontier Health Corporation /United Family Healthcare 2021-12-06 21:44
Broncus Completed the First-in-man Clinical Trial of Its Targeted Lung Denervation Radiofrequency Ablation System 2021-09-30 19:40
Broncus Lists on Main Board of HKEx 2021-09-24 11:52
1